TruScreen launches proactive cervical cancer screening initiative in Ho Chi Minh City
Cervical cancer screening device developer TruScreen Group (ASX: TRU) is set to undertake a major screening program with its technology in Vietnam.
The Sydney-based company has signed a memorandum of understanding (MoU) to implement and conduct a public cervical cancer screening program in Ho Chi Minh City targeting 260,000 women.
The program will implement a proactive screening model where a selected team contacts women directly to encourage them to attend screenings and raises awareness of the high mortality risk from cervical cancer.
Screening program
The program will screen patients in existing district health centres and community health clinics, with the potential to include mobile screening.
The aim is to also support and monitor patients with positive test results to ensure they attend follow-up treatment and continue screening throughout their lives.
The Ho Chi Minh City Public Health Association selected TruScreen due to its unique real-time, non-invasive, objective cervical cancer screening technology that requires no pathology infrastructure and suits the screening program.
Real-time results
The system’s portability, ease of use and analytical algorithms providing real-time results allow the program to achieve early detection in large populations.
“The signing of this MoU further reinforces our TruScreen non-invasive and real-time screening as a technology particularly suited for use in low- and middle-income countries,” TruScreen chief executive officer Marty Dillon said.
“We are increasingly recognised by key government agencies for the ability of TruScreen to be rolled out quickly and economically in large population-based screening programs.”
WHO recognition
The success in Vietnam follows TruScreen’s recognition by a number of international bodies.
The company is now included in guidelines published by the World Health Organisation (WHO), UNITAID and programs in various countries including China, Mexico, Vietnam and Russia.
WHO also recently invited TruScreen to present at an artificial intelligence (AI) cervical cancer screening conference in Edinburgh in November.